Ivax Glucovance ANDA Approved; Inventory Build-Up Underway
This article was originally published in The Pink Sheet Daily
The company holds first-to-file rights for generic of Bristol's antidiabetic, which lost marketing exclusivity Jan. 31.
You may also be interested in...
Ivax launched its generic version of Bristol-Myers Squibb's Glucovance (glyburide/metformin) May 4, triggering 180 days of marketing exclusivity
AMAG outlines plans for retrospective real-world evidence studies, and possibly a new placebo-controlled trial with a primary endpoint of preterm birth <32 weeks, in a filing opposing the Center for Drug Evaluation and Research’s proposal to withdraw the drug.